{"id":"oxaliplatin-during-radiotherapy","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Peripheral neuropathy"},{"rate":"30-40","effect":"Nausea and vomiting"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"20-30","effect":"Myelosuppression"},{"rate":"30-40","effect":"Fatigue"},{"rate":"15-25","effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL414804","moleculeType":"Small molecule","molecularWeight":"395.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxaliplatin binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription. When administered concurrently with radiotherapy, it acts as a radiosensitizer, potentiating the cytotoxic effects of ionizing radiation by inhibiting DNA repair mechanisms and increasing apoptosis in cancer cells.","oneSentence":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, and when combined with radiotherapy, enhances radiation-induced cell death through synergistic DNA damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:03.431Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced colorectal cancer (in combination with radiotherapy)"},{"name":"Rectal cancer (neoadjuvant chemoradiotherapy)"}]},"trialDetails":[{"nctId":"NCT05825066","phase":"PHASE2","title":"Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-08-01","conditions":"Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma","enrollment":64},{"nctId":"NCT04248452","phase":"PHASE3","title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-05-26","conditions":"Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","enrollment":314},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT04808323","phase":"PHASE1","title":"MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-06-17","conditions":"Rectal Adenocarcinoma","enrollment":22},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT06647680","phase":"PHASE2","title":"Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2025-06-01","conditions":"Rectal Cancer Patients","enrollment":35},{"nctId":"NCT07448142","phase":"PHASE2","title":"Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-15","conditions":"Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT06048484","phase":"PHASE2","title":"Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Gulam Manji","startDate":"2024-05-10","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT04928807","phase":"PHASE3","title":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-07-20","conditions":"Rectal Cancer","enrollment":231},{"nctId":"NCT06384560","phase":"PHASE1, PHASE2","title":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2024-09-23","conditions":"Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma","enrollment":66},{"nctId":"NCT07113275","phase":"PHASE3","title":"A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-02-11","conditions":"Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy","enrollment":435},{"nctId":"NCT07397442","phase":"PHASE2","title":"Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2026-03-01","conditions":"Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":19},{"nctId":"NCT03516708","phase":"PHASE1, PHASE2","title":"Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-06","conditions":"Rectal Cancer","enrollment":49},{"nctId":"NCT05412082","phase":"PHASE1","title":"SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2022-10-05","conditions":"Locally Advanced Rectal Cancer","enrollment":25},{"nctId":"NCT04749108","phase":"PHASE2, PHASE3","title":"Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-11-26","conditions":"Locally Advanced Malignant Neoplasm, Rectal Carcinoma","enrollment":1075},{"nctId":"NCT04130854","phase":"PHASE2","title":"INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2020-04-24","conditions":"Locally Advanced Rectal Adenocarcinoma","enrollment":58},{"nctId":"NCT04643366","phase":"PHASE2","title":"Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2021-01-28","conditions":"Rectal Cancer","enrollment":54},{"nctId":"NCT07312422","phase":"PHASE1, PHASE2","title":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2025-09-30","conditions":"Pancreatic Cancer, PD-L1, PD-1 Inhibitor","enrollment":10},{"nctId":"NCT07265674","phase":"PHASE3","title":"A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer","status":"RECRUITING","sponsor":"J-Pharma Co., Ltd.","startDate":"2026-01","conditions":"Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)","enrollment":480},{"nctId":"NCT06468280","phase":"PHASE2","title":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-11-08","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":84},{"nctId":"NCT07347951","phase":"PHASE2","title":"A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-12-01","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":30},{"nctId":"NCT03875781","phase":"PHASE3","title":"Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-06-05","conditions":"Rectal Cancer, Advanced Cancer","enrollment":540},{"nctId":"NCT00335816","phase":"PHASE2","title":"Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-08","conditions":"Colorectal Cancer","enrollment":248},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT03801876","phase":"PHASE3","title":"Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2019-06-26","conditions":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8","enrollment":300},{"nctId":"NCT05108428","phase":"EARLY_PHASE1","title":"Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-12-23","conditions":"Rectal Adenocarcinoma","enrollment":20},{"nctId":"NCT07297030","phase":"PHASE2","title":"SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-20","conditions":"Rectal Cancer","enrollment":37},{"nctId":"NCT07291401","phase":"PHASE2","title":"Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC","status":"NOT_YET_RECRUITING","sponsor":"Zhongnan Hospital","startDate":"2026-01-01","conditions":"Rectal Cancer Patients","enrollment":108},{"nctId":"NCT04417699","phase":"PHASE2","title":"SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2022-07-05","conditions":"Rectal Cancer","enrollment":13},{"nctId":"NCT02921256","phase":"PHASE2","title":"Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-11","conditions":"Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7","enrollment":363},{"nctId":"NCT05358704","phase":"PHASE2","title":"Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer","status":"SUSPENDED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-05-13","conditions":"Cancer of Rectum","enrollment":38},{"nctId":"NCT07239466","phase":"PHASE2","title":"A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-01","conditions":"Rectal Cancer, Radiotherapy, Immunotherapy","enrollment":48},{"nctId":"NCT03777813","phase":"PHASE2","title":"Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2018-12-05","conditions":"Esophagus Cancer, Unresectable Malignant Neoplasm","enrollment":112},{"nctId":"NCT05627635","phase":"PHASE1, PHASE2","title":"FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-05-03","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma","enrollment":20},{"nctId":"NCT04703101","phase":"PHASE1","title":"Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-02-11","conditions":"Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8","enrollment":25},{"nctId":"NCT04821284","phase":"PHASE1, PHASE2","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Flemming Forsberg","startDate":"2021-12-06","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":120},{"nctId":"NCT03776487","phase":"PHASE2","title":"Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-07","conditions":"Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8","enrollment":32},{"nctId":"NCT03904043","phase":"NA","title":"Non-Operative Management and Early Response Assessment in Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-07-01","conditions":"Adenocarcinoma of the Lower Rectum","enrollment":63},{"nctId":"NCT03563248","phase":"PHASE2","title":"Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2018-08-10","conditions":"Pancreatic Cancer","enrollment":168},{"nctId":"NCT07175636","phase":"PHASE2","title":"QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-20","conditions":"Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal Cancer","enrollment":66},{"nctId":"NCT05610163","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-12-08","conditions":"Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":783},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT07134101","phase":"PHASE2","title":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Colorectal Cancer (Diagnosis)","enrollment":138},{"nctId":"NCT02008656","phase":"PHASE2","title":"Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-11","conditions":"Rectal Cancer","enrollment":358},{"nctId":"NCT07070076","phase":"NA","title":"A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Li Qiang","startDate":"2026-08-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":286},{"nctId":"NCT07018570","phase":"PHASE2","title":"An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2025-07-24","conditions":"Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":26},{"nctId":"NCT07132463","phase":"PHASE3","title":"Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-08","conditions":"Rectal Cancer","enrollment":154},{"nctId":"NCT07118800","phase":"PHASE3","title":"Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2025-12-15","conditions":"Locally Advanced Rectal Adenocarcinoma","enrollment":160},{"nctId":"NCT07070622","phase":"PHASE3","title":"Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-11-01","conditions":"Rectal Cancer","enrollment":186},{"nctId":"NCT06719362","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies","status":"RECRUITING","sponsor":"Providence Health & Services","startDate":"2025-06-17","conditions":"Advanced Solid Tumors","enrollment":110},{"nctId":"NCT04594772","phase":"PHASE2","title":"Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2021-03-17","conditions":"Pancreas Cancer","enrollment":32},{"nctId":"NCT04864067","phase":"PHASE2","title":"No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Servicio de Salud Metropolitano Sur Oriente","startDate":"2021-06-09","conditions":"Rectal Cancer","enrollment":73},{"nctId":"NCT06780787","phase":"PHASE2","title":"FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-05-20","conditions":"Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":26},{"nctId":"NCT07040098","phase":"PHASE2","title":"Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-01","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":228},{"nctId":"NCT06850090","phase":"PHASE3","title":"Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-07-30","conditions":"Rectal Cancer, Rectal Cancer Patients","enrollment":210},{"nctId":"NCT01804790","phase":"PHASE3","title":"Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-01","conditions":"Cancer of the Rectum","enrollment":461},{"nctId":"NCT06209099","phase":"NA","title":"Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-01-17","conditions":"Rectal Cancer","enrollment":96},{"nctId":"NCT05253846","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2022-01-25","conditions":"Locally Advanced Rectal Cancer","enrollment":63},{"nctId":"NCT05851924","phase":"PHASE2","title":"A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-05-12","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT06911684","phase":"PHASE2","title":"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-30","conditions":"Rectal Cancer Patients","enrollment":88},{"nctId":"NCT06931808","phase":"PHASE4","title":"Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-03-01","conditions":"Localized Advanced Rectal Adenocarcinoma","enrollment":20},{"nctId":"NCT06214572","phase":"PHASE2, PHASE3","title":"Radiation Therapy in Unresectable Gall Bladder Cancer","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2024-03-07","conditions":"Gall Bladder Cancer","enrollment":249},{"nctId":"NCT06718543","phase":"PHASE2","title":"Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"fan li","startDate":"2025-02-10","conditions":"Rectal Cancer","enrollment":100},{"nctId":"NCT06417476","phase":"PHASE2","title":"Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer","status":"RECRUITING","sponsor":"Pei-Rong Ding","startDate":"2022-12-12","conditions":"Rectal Neoplasms","enrollment":66},{"nctId":"NCT06521866","phase":"PHASE2","title":"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-01","conditions":"Advanced Colorectal Carcinoma, Immunotherapy","enrollment":208},{"nctId":"NCT04365036","phase":"PHASE3","title":"A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-05-03","conditions":"NK/T Cell Lymphoma Nos","enrollment":207},{"nctId":"NCT06246344","phase":"","title":"Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2023-12-01","conditions":"Rectal Cancer","enrollment":128},{"nctId":"NCT06872606","phase":"PHASE2","title":"Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-04-01","conditions":"Rectal Adenocarcinoma","enrollment":33},{"nctId":"NCT06867432","phase":"PHASE2","title":"Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-03-01","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT04460352","phase":"PHASE3","title":"Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2020-11-27","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":1020},{"nctId":"NCT06853769","phase":"EARLY_PHASE1","title":"Neoadjuvant Therapy for Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-09-01","conditions":"Colorectal Cancer","enrollment":48},{"nctId":"NCT01643070","phase":"PHASE2","title":"Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2010-01","conditions":"Rectal Cancer, Liver Metastases","enrollment":38},{"nctId":"NCT02972372","phase":"NA","title":"Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2016-11","conditions":"Esophagus Cancer","enrollment":196},{"nctId":"NCT05296005","phase":"PHASE1","title":"Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers","status":"WITHDRAWN","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2025-12-31","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8","enrollment":""},{"nctId":"NCT01821612","phase":"EARLY_PHASE1","title":"Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2013-05-29","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":23},{"nctId":"NCT06758830","phase":"PHASE2, PHASE3","title":"Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","status":"RECRUITING","sponsor":"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos","startDate":"2025-01-07","conditions":"Rectal Cancer, Total Neoadjuvant Treatment, Neoadjuvant Therapy","enrollment":400},{"nctId":"NCT04375605","phase":"PHASE3","title":"Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsmedizin Mannheim","startDate":"2020-06-03","conditions":"Gastroesophageal Junction Adenocarcinoma","enrollment":342},{"nctId":"NCT05601505","phase":"PHASE2","title":"Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-02-03","conditions":"Locally Advanced Rectal Carcinoma, Circulating Tumor DNA","enrollment":470},{"nctId":"NCT03781323","phase":"PHASE2","title":"Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester","startDate":"2019-05-03","conditions":"Advanced Rectal Cancer","enrollment":12},{"nctId":"NCT05000697","phase":"NA","title":"Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait","status":"RECRUITING","sponsor":"Hospital Alemão Oswaldo Cruz","startDate":"2021-07-14","conditions":"Rectal Cancer, Consolidation","enrollment":216},{"nctId":"NCT06669078","phase":"PHASE2","title":"NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-10-30","conditions":"Locally Advanced Pancreatic Cancer","enrollment":120},{"nctId":"NCT06599827","phase":"PHASE2","title":"Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-09-20","conditions":"Rectal Cancer","enrollment":54},{"nctId":"NCT06594692","phase":"PHASE2","title":"Node-Sparing Short-Course Radiation with CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: a Randomized, Prospective, Multicenter Study","status":"NOT_YET_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-10","conditions":"Microsatellite Stable (MSS) Colon Cancer, Locally Advanced Colon Cancer","enrollment":140},{"nctId":"NCT01404156","phase":"PHASE2, PHASE3","title":"Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Dr. Gordon Buduhan","startDate":"2015-09","conditions":"Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction","enrollment":29},{"nctId":"NCT01595321","phase":"PHASE2","title":"Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-10-29","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT06502080","phase":"PHASE2","title":"Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-07","conditions":"Biliary Tract Cancer","enrollment":128},{"nctId":"NCT06494514","phase":"NA","title":"NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Du Juan","startDate":"2024-04-01","conditions":"Locally Advanced Pancreatic Cancer","enrollment":40},{"nctId":"NCT01274962","phase":"PHASE2","title":"A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer","status":"COMPLETED","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2009-11","conditions":"Operable T2-3N+M0 Rectal Cancer (Stage III)","enrollment":180},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT03300544","phase":"PHASE1","title":"Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-14","conditions":"Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectal Adenocarcinoma","enrollment":3},{"nctId":"NCT02509286","phase":"PHASE3","title":"Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Schleswig-Holstein","startDate":"2016-01","conditions":"Esophageal Adenocarcinoma (UICC TNM7), Adenocarcinoma of the Esophagogastric Junction","enrollment":438},{"nctId":"NCT06390982","phase":"PHASE2","title":"Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05","conditions":"RECTAL NEOPLASMS, Rectal Cancer","enrollment":46},{"nctId":"NCT04301557","phase":"PHASE2","title":"PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-07-31","conditions":"DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Locally Advanced Colorectal Cancer","enrollment":25},{"nctId":"NCT05228431","phase":"PHASE2","title":"Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Zhen-Hai Lu","startDate":"2022-03-02","conditions":"Advanced Rectal Cancer","enrollment":121},{"nctId":"NCT01827553","phase":"PHASE3","title":"Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2013-04-04","conditions":"Pancreatic Cancer","enrollment":830},{"nctId":"NCT04543695","phase":"PHASE2","title":"A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-08-15","conditions":"Rectal Cancer","enrollment":255},{"nctId":"NCT02735239","phase":"PHASE1, PHASE2","title":"Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer","status":"COMPLETED","sponsor":"Ludwig Institute for Cancer Research","startDate":"2016-06-24","conditions":"Esophageal Cancer","enrollment":73},{"nctId":"NCT02128100","phase":"PHASE2","title":"Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2014-09-19","conditions":"Pancreatic Cancer Non-resectable","enrollment":5},{"nctId":"NCT06250894","phase":"PHASE2","title":"Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-03-30","conditions":"PD-1, Neoadjuvant Chemoradiotherapy, Gastroesophageal Junction Cancer","enrollment":32},{"nctId":"NCT05912075","phase":"PHASE1","title":"Preoperative Radiotherapy And ASTX660 in Rectum Cancer","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2023-12-19","conditions":"Locally-advanced Rectal Cancer","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oxaliplatin during radiotherapy","genericName":"Oxaliplatin during radiotherapy","companyName":"Universitätsmedizin Mannheim","companyId":"universit-tsmedizin-mannheim","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, and when combined with radiotherapy, enhances radiation-induced cell death through synergistic DNA damage. Used for Locally advanced colorectal cancer (in combination with radiotherapy), Rectal cancer (neoadjuvant chemoradiotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}